Creso Pharma Limited
Melodiol Global Health Limited engages in the development, cultivation, and distribution of recreational and medical cannabis products in Europe, Canada, Australia, and the Asia Pacific. It is involved in the development and commercialisation of nutraceutical products; and medical supplies business. The company was formerly known as Creso Pharma Limited and changed its name to Melodiol Global Hea… Read more
Creso Pharma Limited (COPHF) - Net Assets
Latest net assets as of December 2023: $-4.06 Million USD
Based on the latest financial reports, Creso Pharma Limited (COPHF) has net assets worth $-4.06 Million USD as of December 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($19.04 Million) and total liabilities ($23.10 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-4.06 Million |
| % of Total Assets | -21.31% |
| Annual Growth Rate | N/A |
| 5-Year Change | -123.49% |
| 10-Year Change | N/A |
| Growth Volatility | 195.62 |
Creso Pharma Limited - Net Assets Trend (2015–2023)
This chart illustrates how Creso Pharma Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Creso Pharma Limited (2015–2023)
The table below shows the annual net assets of Creso Pharma Limited from 2015 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-4.06 Million | -118.20% |
| 2022-12-31 | $22.29 Million | -19.69% |
| 2021-12-31 | $27.76 Million | +103.33% |
| 2020-12-31 | $13.65 Million | -20.97% |
| 2019-12-31 | $17.27 Million | +4.66% |
| 2018-12-31 | $16.50 Million | -21.51% |
| 2017-12-31 | $21.03 Million | +549.06% |
| 2016-12-31 | $3.24 Million | -44.87% |
| 2016-06-30 | $5.88 Million | +54658.45% |
| 2015-12-31 | $-10.77K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Creso Pharma Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16984842800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $150.47 Million | % |
| Other Comprehensive Income | $15.33 Million | % |
| Total Equity | $-4.06 Million | 100.00% |
Creso Pharma Limited Competitors by Market Cap
The table below lists competitors of Creso Pharma Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
WI Co. Ltd.
KQ:073570
|
$1.53 Million |
|
Spartoo SAS
PA:ALSPT
|
$1.53 Million |
|
Emico Holdings Bhd
KLSE:9091
|
$1.53 Million |
|
TCI Finance Limited
NSE:TCIFINANCE
|
$1.53 Million |
|
Canada Rare Earth Corp
PINK:RAREF
|
$1.53 Million |
|
General de Galerias Comerciales SOCIMI S.A.
MC:GGC
|
$1.53 Million |
|
Izolacja Jarocin SA
WAR:IZO
|
$1.53 Million |
|
EFXB31
SA:EFXB31
|
$1.52 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Creso Pharma Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 22,294,000 to -4,058,000, a change of -26,352,000 (-118.2%).
- Net loss of 52,446,000 reduced equity.
- Share repurchases of 699,000 reduced equity.
- New share issuances of 5,124,000 increased equity.
- Other comprehensive income decreased equity by 5,178,000.
- Other factors increased equity by 26,847,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-52.45 Million | -1292.41% |
| Share Repurchases | $699.00K | -17.23% |
| Share Issuances | $5.12 Million | +126.27% |
| Other Comprehensive Income | $-5.18 Million | -127.6% |
| Other Changes | $26.85 Million | +661.58% |
| Total Change | $- | -118.20% |
Book Value vs Market Value Analysis
This analysis compares Creso Pharma Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-06-30 | $0.00 | $0.12 | x |
| 2016-12-31 | $0.10 | $0.12 | x |
| 2017-12-31 | $0.25 | $0.12 | x |
| 2018-12-31 | $0.15 | $0.12 | x |
| 2019-12-31 | $0.12 | $0.12 | x |
| 2020-12-31 | $0.04 | $0.12 | x |
| 2021-12-31 | $0.03 | $0.12 | x |
| 2022-12-31 | $0.02 | $0.12 | x |
| 2023-12-31 | $-0.87 | $0.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Creso Pharma Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -277.18%
- • Asset Turnover: 0.99x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-105.28%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-137.79K |
| 2016 | -141.50% | -57145.84% | 0.00x | 1.16x | $-4.91 Million |
| 2017 | -71.69% | -6183.84% | 0.01x | 1.03x | $-17.18 Million |
| 2018 | -100.98% | -2897.86% | 0.03x | 1.34x | $-18.42 Million |
| 2019 | -96.63% | -470.25% | 0.16x | 1.28x | $-18.82 Million |
| 2020 | -275.25% | -1535.17% | 0.13x | 1.40x | $-38.94 Million |
| 2021 | -114.44% | -510.84% | 0.21x | 1.06x | $-34.54 Million |
| 2022 | -147.04% | -377.28% | 0.23x | 1.70x | $-35.01 Million |
| 2023 | 0.00% | -277.18% | 0.99x | 0.00x | $-52.04 Million |
Industry Comparison
This section compares Creso Pharma Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Creso Pharma Limited (COPHF) | $-4.06 Million | 0.00% | N/A | $1.53 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |